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ABSTRACT
Objective: Reliable and valid needs assessment measures
are important assessment tools in cancer survivorship care.
A new 30‑item short‑form version of the Survivor Unmet
Needs Survey (SF‑SUNS) was developed and validated with
cancer survivors, including hematology cancer survivors;
however, test–retest reliability has not been established. The
objective of this study was to assess the test–retest reliability
of the SF‑SUNS with a cohort of lymphoma survivors (n = 40).
Methods: Test–retest reliability of the SF‑SUNS was conducted
at two time points: baseline (time 1) and 5 days later
(time 2). Test–retest data were collected from lymphoma cancer
survivors (n = 40) in a large tertiary cancer center in Western
Australia. Intraclass correlation analyses compared data at time
1 (baseline) and time 2 (5 days later). Cronbach’s alpha analyses
were performed to assess the internal consistency at both time
points. Results: The majority (23/30, 77%) of items achieved
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test–retest reliability scores 0.45–0.74 (fair to good). A high
degree of overall internal consistency was demonstrated
(time 1 = 0.92, time 2 = 0.95), with scores 0.65–0.94 across
subscales for both time points. Conclusions: Mixed test–retest
reliability of the SF‑SUNS was established. Our results indicate
the SF‑SUNS is responsive to the changing needs of lymphoma
cancer survivors. Routine use of cancer survivorship specific
needs‑based assessments is required in oncology care today.
Nurses are well placed to administer these assessments
and provide tailored information and resources. Further
assessment of test–retest reliability in hematology and other
cancer cohorts is warranted.
Key words: Cancer survivorship, internal consistency,
lymphoma, short‑form Survivor Unmet Needs Survey,
test–retest reliability
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Introduction
Lymphoma blood cancers are malignant T or B cell
lymphocytes in the lymphatic system and are categorized
under two main types: non‑Hodgkin lymphoma (NHL) and
Hodgkin Lymphoma (HL). NHL represents approximately
88% of all lymphomas, while HL is predominately
diagnosed in the adolescent and young adult population.[1]
Combined, they represent the sixth most common cancer
diagnosis worldwide.[1] Consistent with worldwide trends,
the incidence of lymphoma in Australia is increasing,
and with a projected diagnosis of 6232 cases in 2017, this
equates to 4.6% of all cancer cases.[2] An estimated mortality
rate of 1481 equates to 3.1% of all deaths from cancer in
2017.[2] Projected figures for 2017 in the USA have a similar
projected incidence of lymphoma of 4.8% and mortality
of 3.6%.[1] Treatment for lymphoma generally comprises
high‑dose chemotherapy and/or targeted immunotherapy
agents and may include radiotherapy and hematopoietic
stem cell transplants.[3] These treatments have resulted in
an improvement to overall survival of approximately 76%
at 5 years compared with 52% at 5 years in the 1980s.[2]
Notwithstanding the positive impact treatment has had on
survival rates,[4] the consequences of disease and treatment
continue long after treatment completion.[5] Long‑term and
late effects may produce ongoing unmet needs such as fear
of recurrence, fatigue, poor nutrition, exercise, fertility,
relationship, financial, employment, and insurance issues.[6]
To provide optimal supportive cancer care to lymphoma
survivors, the identification of patients’ perceived concerns
and level of support needed is required.[5] This is especially
important for younger patients (18–45 years of age)
where the expectation of long‑term remission can raise
additional concerns and unmet needs.[7] Receiving relevant
information and practical support soon after treatment ends,
especially resources related to healthy lifestyle behaviors,[7‑11]
can help mitigate the impact of disease and treatment and
lead to fewer unmet needs further along the survivorship
continuum.[12,13] A qualitative study with lymphoma cancer
survivors (n = 17) undertaken in Western Australia[14]
reported unmet informational and practical needs as
participants transitioned from treatment to the survivorship
phase. The findings suggested tailored post‑treatment
support and interventions are fundamental components of
excellent survivorship care.
The measures used to assess unmet needs are equally
important. Generic cancer measures which comprise items
related to diagnosis and treatment are often not specific
enough for the survivorship phase.[15] Comprehensive,
relevant, reliable, and validated needs assessment measures
that are survivor‑specific are essential to capture unmet
needs that become evident when treatment ends.[15] These
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measures can guide health professionals in providing
individualized information, support, and resources.[5,15]
Two recent systematic reviews[15,16] revealed that needs
assessment tools are varied and may not capture all the
possible unmet needs patients may have. The reviews
likewise found validity and reliability evidence limited.
The Survivor Unmet Needs Survey (SUNS) was identified
as a measure that had strong psychometric properties
and was developed and psychometrically tested with a
large cross‑sectional sample of cancer survivors (n = 550)
including a small cohort of hematology cancer participants
(n = 31, 5.6%).[17] Campbell et al.[17] confirmed a high
overall internal consistency of items for their study with an
overall Cronbach’s alpha of 0.99. The authors also reported
high test–retest reliability although the results were not
published.[17] Internal consistency of the SUNS was further
tested in two studies of hematological cancer survivor
cohorts. A cross‑sectional study with 529 hematological
cancer survivors [18] demonstrated overall Cronbach’s
alpha values >0.9, and a weighted Kappa coefficient
score of >0.6 for test–retest reliability; acceptability was
reported for 40/89 (45%) items. Qualitative data from 17
semi‑structured interviews indicated that the SUNS was
considered relevant by this cohort of hematological cancer
survivors.[18] A cross‑sectional study of hematological
cancer survivors from Australia and Canada (n = 437)
reported similar levels of unmet needs across the two
cohorts using the SUNS, with fatigue (n = 76, 17%) and
financial concerns (n = 39, 9%) rated as high unmet
needs.[9] Despite the clinical utility of the original SUNS,
it was considered potentially burdensome for use in the
clinical setting given the large number of items (n = 89).
In 2014, the 30‑item short‑form‑SUNS (SF‑SUNS) was
developed and validated with a mixed sample of cancer
survivors (n = 1589), including hematological cancer
survivors (n = 84, 5%).[5] Construct validity and intraclass
correlation coefficients (ICCs) of the SF. were similar to
those of the original SUNS. Cronbach’s alpha scores for
the final four domains were ≥0.85, and ICCs for the three
domains from the original SUNS (financial concerns,
information, and access and continuity of care) and
the SF‑SUNS were high (>0.9). Discriminant validity
demonstrated the SF‑SUNS ability to discriminate between
individuals who had recently received treatment and those
who had not. The authors recommended further testing
of the SF‑SUNS for test–retest reliability.[5] The 30‑item
SF‑SUNS was therefore judged to be more practical and
likely to be completed by participants in our larger study,
particularly as the SF‑SUNS was one of four instruments
to be administered to participants in a pilot randomized
trial to measure the effect of a nurse‑led survivorship model
of care.[19]
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For researchers and clinicians to develop targeted follow‑up
support for cancer cohorts underrepresented in survivorship
literature, such as lymphoma,[20] cohort‑specific studies in
the early survivorship phase are required.[21] Therefore, this
study recruited only those with a lymphoma diagnosis who
had completed treatment. Discerning the issues and concerns
of this group requires survivor‑specific measures that are
psychometrically sound and fully tested. The SF‑SUNS has
been used within the clinical setting; however, since test–retest
reliability of the SF‑SUNS had not been established, the aim
of the present study was to establish test–retest reliability of
the SFSUNS to add to the psychometric data available in the
published literature on this instrument.

Methods
Design
Test–retest reliability of the SF‑SUNS was conducted at
two time points: baseline (time 1) and 5 days later (time 2).
This time frame was chosen to reduce recall bias and change
in the level of unmet needs.[22] Ethical approval to conduct the
study was obtained from the human research ethics committee
of the study site (2015‑020) and university (015007F).

Population and setting
A convenience sample of 40 lymphoma cancer patients
who were 3 months’ posttreatment completion were
recruited from the hematology department of a large
tertiary hospital in Western Australia. Inclusion criteria
were pathologically confirmed new diagnosis of NHL or
HL; completed first‑line curative intent chemotherapy or
second‑line curative intent autologous stem cell transplant
within the previous 3 months; no radiological evidence
of lymphoma posttreatment (on positron emission
tomography [PET] scan); able to understand and read
English; and over 18 years of age. Participants were excluded
if they had not been treated with chemotherapy; had received
further treatment at another hospital (as experiences or
interventions may have introduced bias); or were cognitively
impaired or experiencing an acute mental health condition
that prohibited the provision of informed consent.

Sample size
The sample size calculation was derived from Walter
et al.[23] and used a fixed alpha of 0.05 from two observations
with reliability values of R0 = 0.6 (acceptable) and
R1 = 0.8 (expected), indicating a minimum sample size
of n = 39.

Short‑form Survivor Unmet Needs Survey
The SF‑SUNS assesses unmet needs across four domains:
information needs (3 items); work and financial needs

(8 items); access and continuity of care needs (6 items); and
coping, sharing, and emotional needs (13 items). Patient
self‑reported concerns and the level of support required
are measured using a Likert‑type scale: 0 – no unmet need,
1 – low unmet need, 2 – moderate unmet need, 3 – high
unmet need, and 4 – very high unmet need. Domain scores
are generated by adding each item score and dividing by
the total number of domain items.[24]

Procedure
The researcher identified and approached eligible
participants after treatment completion to discuss the
study and provide them with a participant information and
consent form. Following informed consent, demographic
and baseline (time 1) SF‑SUNS questionnaires were then
administered to participants. After completion of the
questionnaires, participants were provided with another
blank copy of the SF‑SUNS accompanied by instructions
to complete the questionnaire at home 5 days later and
postback using the supplied reply‑paid addressed envelope.
Participants were advised to record the date of completion
if this differed from the specified due date.

Data collection
At the request of the research team’s hematologist,
baseline demographic and SF‑SUNS data were collected
from consenting participants 3 months posttreatment
completion and PET scan to confirm the absence of
disease. Demographic information obtained included
lymphoma type, stage of disease, type of treatment
received (chemotherapy +/− radiotherapy), date of
diagnosis, time since diagnosis, comorbid conditions,
gender, age, weight, marital status, age of children (if any),
postcode, occupation, income level, education level, and
health behaviors such as smoking and alcohol consumption.
Participants then completed the SF‑SUNS at time 2
(5 days following time 1 completion) at home.

Data analysis
All analyses were performed using IBM SPSS Statistics
Version 25 data analysis software (IBM Corp. Released
2017. IBM SPSS Statistics for Macintosh, Version 25.0.
Armonk, NY: IBM Corp). Descriptive statistics were
used to analyze all data. Descriptive analyses were used
to analyze and describe demographic data. To assess for
absolute consistency of SF‑SUNS items for test–retest
reliability data, an ICC with a random‑effects model was
used to compare each item at time 1 and time 2. The ICC
measure was chosen for its ability to discriminate between
sets of scores ranked in the same order but not necessarily in
agreement and adjusts for the degree of test–retest agreement
expected by chance.[25,26] The closer the value of the ICC
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to 1.0, the greater the reliability of the item or measure.[27]
The guidelines developed by Cicchetti and Sparrow[28] were
used to determine the level of clinical significance of
the ICC values obtained: <0.40 = poor, 0.40–0.59 = fair,
0.60–0.74 = good, and >0.75 = excellent. For this study,
items classified as achieving “fair to excellent” reliability,
ICC >0.40,[29] were reported. Cronbach’s alpha, a measure of
internal consistency, was used to measure the scale reliability.
To examine the distribution of unmet needs, the
five levels of unmet need were collapsed to three levels.
A score of 0 (no unmet need) remained the same. Scores
of 1 or 2 (low and moderate unmet need) were reclassified
as 1 (low–moderate unmet need), and scores of 3 or 4
(high and very high unmet need) were classified as 2
(high–very high unmet need).

Results
There were slightly more male (n = 22, 55%) participants,
and a greater number of participants with NHL
(n = 29, 72.5%) compared with HL (n = 11, 27.5%) [Table 1].
This was in keeping with the current disease statistics which
reflect a greater number of NHL than HL diagnoses.[1]
Almost one‑third of participants were aged between 18 and
39 years (32.5%), and a greater proportion had a university
Table 1: Baseline participant demographic and disease
characteristics (n=40)
n (%)

Gender
Male

22 (55.0)

Female

18 (45.0)

Age group (years)
18‑39

13 (32.5)

40‑59

12 (30.0)

60‑74

9 (22.5)

75+

6 (15.0)

Marital status
Single

10 (25.0)

Married/de facto

25 (62.5)

Divorced

3 (7.5)

Widowed

2 (5.0)

Lymphoma diagnosis
Non-Hodgkin

29 (72.5)

Hodgkin

11 (27.5)

Highest level of education
Secondary school or less

11 (27.5)

Trade, vocational college

13 (32.5)

University or higher

16 (40.0)

Employment status
Working

15 (37.5)

Retired

13 (32.5)

Looking for work/no return to work date

12 (30.0)
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Test–retest
ICCs, 95% confidence intervals, and clinical significance
are shown in Table 2. One (3%) item met the “excellent”
criteria for clinical significance; Finding car parking I can
afford at the hospital or clinic. Twelve (40%) items met the
“good” criteria (0.60–0.74) and 11 (37%) items met the “fair”
criteria (0.40–0.59). In summary, test–retest data showed “fair”
to “good” reliability for the majority of items (23/30, 77%).

Internal consistency

Participant characteristic

Characteristics

qualification (n = 16, 40%) [Table 1]. Although the majority
of participants were currently working (n = 15, 37.5%) and
had been throughout their treatment, 30% (n = 12) were
looking for work or had no return to work date set. Over
half the participants had a partner (n = 25, 62.5%). Forty
participants completed both time 1 and time 2 SF‑SUNS.
The majority of participants (n = 35, 87.5%) completed time
2 SF‑SUNS 5 days after time 1 (range 4–7 days).

Overall Cronbach’s alphas were 0.92 at time 1 and
0.94 at time 2, with subscales [Table 2] ranging from
0.74 and 0.69 for information needs, 0.65 and 0.83 for
work and financial needs, 0.89 and 0.85 for access and
continuity of care, and 0.90 and 0.94 for coping, sharing,
and emotional needs, respectively. These results support
strong internal consistency for the overall scale. Item‑to‑total
correlations between 0.40 and 0.70 indicate that items
are not redundant or measuring needs similar to other
items within the instrument.[30] Using this criterion, the
SF‑SUNS demonstrated item‑to‑total correlations between
0.40 and 0.70 at time 1 for 24 items (80%) and at time 2
for 19 items (63%) [Table 2]. The majority of items were
considered relevant and to be measuring unique needs.

Discussion
Our study is the first to report test–retest data for the
SF‑SUNS. The majority of items met absolute consistency
for reliability ICC scores of >0.40 for test–retest, categorized
as “fair” to “good.” An “excellent” clinical significance
score was achieved for only one item (3%), related to car
parking costs which are unlikely to change over time.
Needs‑based instruments such as the SF‑SUNS measure the
degree of an individual’s perceived unmet need at one point
in time. Importantly, Cronbach’s alpha scores at time 1 and
time 2 demonstrated a high degree of internal consistency
and high item‑to‑total correlations, confirming that items
in the tool were reliable.
A criterion for psychometrically sound needs‑based tools
is the requirement for an instrument to be responsive to
changes over time.[31‑33] Although our ICC results may reflect
the responsiveness of the SF‑SUNS to changes in need
over the data collection period, further research is required
Asia‑Pacific Journal of Oncology Nursing • Volume 5 • Issue 2 • April-June 2018
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Table 2: Item test‑retest reliability and internal consistency (n=40)
Domain (n=4)

Information needs

Work and financial
needs

Item description

Level of clinical Cronbach’s alpha
significance

Items (n=3)

Time 1

Time 2

0.74

0.69

Item‑to‑total
correlation
Time 1

Time 2

Finding information about complementary or alternative
therapies

0.69 (0.49‑0.83)

Good

0.30

0.50

Dealing with fears about cancer spreading

0.56 (0.30‑0.74)

Fair

0.59

0.63

Dealing with worry about whether treatment has
worked

0.57 (0.32‑0.75)

Fair

0.65

0.71

Worry about earning money

0.63 (0.40‑0.79)

Good

0.49

0.47

Having to take a pension or disability allowance

0.39 (0.09‑0.62)

Poor

0.45

0.38

Paying household bills or other payments

0.69 (0.49‑0.83)

Good

0.55

0.60

Finding what type of financial assistance is available and
how to obtain it

0.70 (0.50‑0.83)

Good

0.67

0.71

Finding car parking that I can afford at the hospital or
clinic

0.76 (0.59‑0.86)

Excellent

0.02

0.45

Understanding what is covered by my medical insurance
or benefits

0.31 (0.01‑0.57)

Poor

0.20

0.06

Knowing how much time I would need away from work

0.74 (0.55‑0.85)

Good

0.55

0.50

Doing work around the house (cooking, cleaning, home
repairs, etc.)

0.37 (0.07‑0.61)

Poor

0.12

0.70

0.45 (0.16‑0.66)

Fair

0.44

0.62

Getting appointments with specialists quickly
enough (oncologist, surgeon, etc.)

0.38 (0.08‑0.61)

Poor

0.70

0.44

Getting test results quickly enough

0.66 (0.44‑0.81)

Good

0.57

0.51

Having access to care from other health
specialists (dietitians, physiotherapists, occupational
therapists)

0.53 (0.26‑0.72)

Fair

0.51

0.67

Making sure I had enough time to ask my doctor or
nurse questions

0.58 (0.33‑0.75)

Fair

0.59

0.48

Getting the health care team to attend promptly to my
physical needs

0.53 (0.26‑0.72)

Fair

0.59

0.50

0.43 (0.14‑0.65)

Fair

0.58

0.48

0.33 (0.02 to 0.58)

Poor

0.45

0.57

Dealing with people who expect me to be “back to
normal”

0.62 (0.39‑0.78)

Good

0.57

0.77

Dealing with people accepting that having cancer has
changed me as a person

0.51 (0.24‑0.71)

Fair

0.68

0.81

Dealing with reduced support from others when
treatment has ended

0.67 (0.46‑0.81)

Good

0.82

0.82

Dealing with feeling depressed

0.73 (0.55‑0.85)

Good

0.53

0.72

Dealing with feeling tired

0.49 (0.21‑0.69)

Fair

0.57

0.71

Dealing with feeling stressed

0.55 (0.29‑0.74)

Fair

0.78

0.69

Dealing with feeling lonely

0.72 (0.52‑0.84)

Good

0.53

0.61

Dealing with not being able to feel “normal”

0.47 (0.20‑0.68)

Fair

0.57

0.70

Trying to stay positive

0.63 (0.40‑0.79)

Good

0.55

0.65

Coping with having a bad memory or lack of focus

0.64 (0.41‑0.79)

Good

0.50

0.86

0.28 (−0.04‑0.54)

Poor

0.23

0.24

Items (n=8)

Access and continuity Items (n=6)
of care
Having access to cancer services close to my home

Coping, sharing and
emotional needs

ICC (95% CI)

0.65

0.89

Items (n=13)
Telling others how I was feeling emotionally
Finding someone to talk to who understands and has
been through a similar experience

Dealing with changes in how my body appears

0.90

0.83

0.85

0.94

ICC: Intraclass correlation, CI: Confidence interval

to detect clinically meaningful change for patients.[16] All
participants completed the time 2 questionnaire at home,
well away from the hematology clinic where the time 1
questionnaire was completed. It is possible that participants
may have had additional time to more accurately reflect

on the level of unmet need. Similarly, time 1 scores may
have been impacted by participants’ anxiety at the hospital
appointment where patients often worry about test results
and potential relapse.[34] In addition, fatigue is a recognized
effect of lymphoma treatment[7] and may have potentially
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affected participant responses at either time point. Finally,
most items were similarly balanced for both time points
from “no unmet need” to “low unmet need” or “low unmet
need” to “no unmet need.”
It is important to allow cancer survivors the opportunity to
self‑identify unmet needs and issues of concern. Survivorship
needs‑based instruments provide a consistent method for
this purpose.[35] Furthermore, it is important that any tool
is responsive to change as individuals’ issues, concerns,
thoughts, and feelings can change from day‑to‑day,[32,33]
particularly during survivorship transition as individuals
move on with their lives after cancer treatment. Such
reliable and valid instruments can facilitate individualized
survivorship care and tailored support and resources.[15]
It is important to note that the original SUNS
demonstrated low test–retest reliability acceptability,[18]
with the authors suggesting that the test–retest timeframe
was too long at 28 days. Since our study was part of a
larger study involving an intervention group, a 5‑day
later test–retest assessment was deemed an appropriate
timeframe to ensure completion of the time 2 SF‑SUNS
before the implementation of any needs‑based interventions
associated with the larger study.[19] Importantly, this time
period was also in keeping with the recommended 2–14‑day
time period for test–retest procedures.[31‑33]
A limitation of this study may have been the sample
size of 40 participants, despite sample size calculations
indicating that this number would be sufficient to adequately
perform test–retest reliability with confidence. Many
participants (n = 16, 40%) attended the baseline appointment,
where time 1 SF‑SUNS was administered, accompanied by a
support person (partner or family member). We acknowledge
that this may have influenced time 1 responses. Likewise,
time 2 responses may have similarly been influenced as the
SF‑SUNS was completed at home. We can confirm that
participants did not receive any needs‑based interventions
between time 1 and time 2 completion of the SF‑SUNS.

Conclusion
We suggest that needs‑based assessments should
be used routinely during the survivorship period to
facilitate survivorship care that is tailored and responsive
to individuals’ changing needs. Valid and reliable
survivor‑specific measures are essential for routine
screening and follow‑up. Nurses in particular are a
valuable resource in the survivorship phase to assess for
areas of concern or unmet needs and for the provision
of information, support, and resources that are tailored
to the individuals’ unique needs. Further testing of the
SF‑SUNS is recommended in hematology and other cancer
populations to further understand and demonstrate the
170

responsiveness of this instrument to changes in need over
the survivorship period.
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